Janssen will not seek regulatory approval for Erleada plus Zytiga in prostate cancer

activity may derive ‘clinical benefit’ from the Erleada/Zytiga combination treatment, according to Janssen. ... However, Janssen disclosed yesterday that the Erleada/Zytiga combination treatment did not demonstrate significant benefit over Zytiga

Janssen’s Erleada improves survival in certain advanced prostate cancer patients

Androgen inhibitor Erleada (apalutamide) is Janssen’s follow-up to its older, blockbuster prostate cancer drug Zytiga (abiraterone acetate), which has now been hit by the loss of patent protection and

Bayer gets EU nod for prostate cancer drug Nubeqa

Nubeqa’s rivals in the prostate cancer market include J&J’s Erleada (apalutamide) – its follow-up to its Zytiga (abirterone) brand which is now threatened by generic competition – and

J&J gets EMA nod for wider use of Erleada in prostate cancer

Androgen inhibitor Erleada (apalutamide) is J&J’s follow-up up to big-selling prostate cancer drug Zytiga (abiraterone acetate), which has been hit by the loss of patent protection and ... Xtandi is now the dominant player in the market by value, with

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]